Ledipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV

Alessia Ciancio

DOI: https://doi.org/10.7175/rhc.v6i3.1178

Abstract

Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications, other reasons for ineligibility and side-effects. The fixed dosed combination ledipasvir/sofosbuvir (LDV / SOF) is the first approved regimen that doesn’t require administration with interferon or ribavirin. LDV / SOF is also the first single-pill approved for the treatment of chronic HCV genotype 1 in both treatment-naïve and treatment-experienced patients. The results of the phase III studies demonstrate the combination has been very well tolerated and SVR rates consistently above 90%. Objective of this review is to present clinical evidence of efficacy and safety of the combination LDV / SOF in different subgroups of patients with HCV.

Keywords

Ledipasvir; Sofosbuvir; HCV

Full Text

HTML PDF

References

  • Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23; http://dx.doi.org/10.1016/S0140-6736(13)62121-2
  • Sovaldi. Riassunto delle caratteristiche di prodotto
  • Harvoni. Riassunto delle caratteristiche di prodotto
  • U.S Food and Drug Administration. FDA approves first combination pill to treat hepatitis C. FDA News Release, ottobre, 2014. Disponibile su: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm (ultimo accesso marzo 2015)
  • European Medicine Agency. Harvoni recommended for the treatment of chronic hepatitis C. Press Release, 26/09/2014
  • Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736-43; http://dx.doi.org/10.1053/j.gastro.2013.11.007
  • Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98; http://dx.doi.org/10.1056/NEJMoa1402454
  • Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93; http://dx.doi.org/10.1056/NEJMoa1316366
  • Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88; http://dx.doi.org/10.1056/NEJMoa1402355
  • Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir/sofosbuvir fixed-dosed combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. 65th Annual Meeting of America Association for the Study of Liver Disease. Boston, 2014: Abstract LB-6
  • Bourlière M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. 65th Annual Meeting of America Association for the Study of Liver Disease. Boston, 2014: abstract 82
  • Flamm SL, Everson GT, Charlton MR, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract 239
  • Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-trasplant recurrence: preliminary results of a prospective, multicenter study. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: Abstract 8
  • Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161; 634-8; http://dx.doi.org/10.7326/M14-1211
  • Rockstroh JK, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HICV coinfected patients with HCV G 1-4 infection: the PHOTON-1 and -2 trials. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: Abstract 195
  • Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1: ION-4. The annual Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, 2015: abstract 152LB
  • Gane EJ, Hyland RH, Anet D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). Londra, 2016: abstract 06
  • Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract LB-11
  • Kapoor R, Kohli A, Sidharthan S, et al. treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. 65th Annual meeting of the American Association for the Study of Liver Diseases. Boston, 2014: abstract 240
  • Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71; http://dx.doi.org/10.1002/hep.20119
  • Incivo. Riassunto delle caratteristiche di prodotto
  • Victrelis. Riassunto delle caratteristiche di prodotto
  • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92; http://dx.doi.org/10.1056/NEJM199811193392101
  • Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32; http://dx.doi.org/10.1016/S0140-6736(98)07124-4
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65; http://dx.doi.org/10.1016/S0140-6736(01)06102-5
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82; http://dx.doi.org/10.1056/NEJMoa020047
  • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55; http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010
  • McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93; http://dx.doi.org/10.1056/NEJMoa0808010
  • Pegasys – Riassunto delle caratteristiche di prodotto
  • Pegintron – Riassunto delle caratteristiche di prodotto
  • Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-1, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1425
  • Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-2, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1413
  • Ferenci P, Asselah T, Foster GR, et al. Falaprevir plus pegylated interferon alfa2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from STARTVERSO1, a randomized, placebo-controlled phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1416
  • Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 221 cirrhotic non-responders treated in the French early access program (ANRS CO20-CUPIC). 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 60
  • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87; http://dx.doi.org/10.1056/NEJMoa1214853
  • Lawitz E, Wyles D, Davis M, et al. Sofosbuvir + peginterferon + ribavirin for 12 weeks achieves 90% SVR12 in genotype 1, 4, 5, or 6 HCV infected patients: The NEUTRINO study. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, 2013: abstract 1411

Statistics

Abstract: 1141 views
HTML: 761 views
PDF: 163 views

Refbacks

  • There are currently no refbacks.




© SEEd srl